BACKGROUND: As with other open procedures now routinely performed using laparoscopy, minimally invasive pancreaticoduodenectomy (MIPD) may result in decreased pain, fewer wound complications, and accelerated recovery. However, when used for periampullary cancers, it is also important to assess if MIPD offers comparable oncologic outcomes. METHODS: Technical and perioperative outcomes were compared between patients with a preoperative diagnosis of periampullary neoplasm offered MIPD or open pancreaticoduodenectomy (OPD) from November 2009 to July 2011. RESULTS: Fifty-six consecutive MIPD and OPD (28 each) procedures were analyzed. Comparing MIPD to OPD, significant differences included longer median procedure time (431 vs 410 min, p = .04) and fewer median lymph nodes harvested (15 vs. 20, p = .04). R0 resection rate tended to be lower (63 vs. 88%, p = .07) as well as surgical site infections (18 vs. 43 %, p = .08). Clinically significant pancreatic fistula rate was the same between groups (21%). Other outcomes such as narcotic pain medication use, length of stay, and 30-day readmission rates were also similar. CONCLUSIONS: MIPD is feasible with comparable technical success and outcomes to OPD. However, there is a learning curve to the procedure and further experience and prospective study will be required to better establish the oncologic efficacy of MIPD to open resection.
BACKGROUND: As with other open procedures now routinely performed using laparoscopy, minimally invasive pancreaticoduodenectomy (MIPD) may result in decreased pain, fewer wound complications, and accelerated recovery. However, when used for periampullary cancers, it is also important to assess if MIPD offers comparable oncologic outcomes. METHODS: Technical and perioperative outcomes were compared between patients with a preoperative diagnosis of periampullary neoplasm offered MIPD or open pancreaticoduodenectomy (OPD) from November 2009 to July 2011. RESULTS: Fifty-six consecutive MIPD and OPD (28 each) procedures were analyzed. Comparing MIPD to OPD, significant differences included longer median procedure time (431 vs 410 min, p = .04) and fewer median lymph nodes harvested (15 vs. 20, p = .04). R0 resection rate tended to be lower (63 vs. 88%, p = .07) as well as surgical site infections (18 vs. 43 %, p = .08). Clinically significant pancreatic fistula rate was the same between groups (21%). Other outcomes such as narcotic pain medication use, length of stay, and 30-day readmission rates were also similar. CONCLUSIONS: MIPD is feasible with comparable technical success and outcomes to OPD. However, there is a learning curve to the procedure and further experience and prospective study will be required to better establish the oncologic efficacy of MIPD to open resection.
Authors: Herbert J Zeh; Amer H Zureikat; Aaron Secrest; Mustapha Dauoudi; David Bartlett; A James Moser Journal: Ann Surg Oncol Date: 2011-09-24 Impact factor: 5.344
Authors: Jennifer F Tseng; Peter W T Pisters; Jeffrey E Lee; Huamin Wang; Henry F Gomez; Charlotte C Sun; Douglas B Evans Journal: Surgery Date: 2007-05 Impact factor: 3.982
Authors: Nicolas Christian Buchs; Pietro Addeo; Francesco Maria Bianco; Subhashini Ayloo; Enrico Benedetti; Pier Cristoforo Giulianotti Journal: World J Surg Date: 2011-12 Impact factor: 3.352
Authors: Susan Tsai; Michael A Choti; Lia Assumpcao; John L Cameron; Ana L Gleisner; Joseph M Herman; Frederic Eckhauser; Barish H Edil; Richard D Schulick; Christopher L Wolfgang; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2010-04-30 Impact factor: 3.452
Authors: Thijs de Rooij; Sjors Klompmaker; Mohammad Abu Hilal; Michael L Kendrick; Olivier R Busch; Marc G Besselink Journal: Nat Rev Gastroenterol Hepatol Date: 2016-02-17 Impact factor: 46.802
Authors: Claudio Ricci; Riccardo Casadei; Giovanni Taffurelli; Carlo Alberto Pacilio; Marco Ricciardiello; Francesco Minni Journal: World J Surg Date: 2018-03 Impact factor: 3.352
Authors: Grace C Lee; Zhi Ven Fong; Cristina R Ferrone; Sarah P Thayer; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo Journal: J Gastrointest Surg Date: 2014-08-05 Impact factor: 3.452